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the Oropharynx
Ankur Chakravarthy, Stephen Henderson, Stephen M. Thirdborough, Christian H. Ottensmeier, Xiaoping Su,
Matt Lechner, Andrew Feber, Gareth J. Thomas, and Tim R. Fenton
A B S T R A C T
Purpose
In squamous cell carcinomas of the head and neck (HNSCC), the increasing incidence of oro-
pharyngeal squamous cell carcinomas (OPSCCs) is attributable to human papillomavirus (HPV)
infection. Despite commonly presenting at late stage, HPV-driven OPSCCs are associated with
improved prognosis compared with HPV-negative disease. HPV DNA is also detectable in non-
oropharyngeal (non-OPSCC), but its pathogenic role and clinical signiﬁcance are unclear. The ob-
jectives of this study were to determine whether HPV plays a causal role in non-OPSCC and to
investigate whether HPV confers a survival beneﬁt in these tumors.
Methods
Meta-analysis was used to build a cross-tissue gene-expression signature for HPV-driven cancer.
Classiﬁers trained by machine-learning approaches were used to predict the HPV status of 520
HNSCCs proﬁled by The Cancer Genome Atlas project. DNAmethylation data were similarly used to
classify 464 HNSCCs and these analyses were integrated with genomic, histopathology, and
survival data to permit a comprehensive comparison of HPV transcript-positive OPSCC and non-
OPSCC.
Results
HPV-driven tumors accounted for 4.1% of non-OPSCCs. Regardless of anatomic site, HPV+
HNSCCs shared highly similar gene expression and DNA methylation proﬁles; nonkeratinizing,
basaloid histopathological features; and lack of TP53 or CDKN2A alterations. Improved overall
survival, however, was largely restricted to HPV-driven OPSCCs, which were associated with in-
creased levels of tumor-inﬁltrating lymphocytes compared with HPV-driven non-OPSCCs.
Conclusion
Our analysis identiﬁed a causal role for HPV in transcript-positive non-OPSCCs throughout the head
and neck. Notably, however, HPV-driven non-OPSCCs display a distinct immune microenvironment
and clinical behavior compared with HPV-driven OPSCCs.
J Clin Oncol 34:4132-4141. © 2016 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/.
INTRODUCTION
High-risk human papillomaviruses (hrHPVs)
infect mucosal epithelia and cause carcinomas at
several anogenital sites, accounting for almost all
cervical cancer cases worldwide.1 HPV is also
a strong independent risk factor for oropharyn-
geal squamous cell carcinoma (OPSCC), a subset
of head and neck cancers that occur in the epi-
thelia lining lymphoid crypts of the tonsils and
tongue base.2 Head and neck squamous cell car-
cinomas (HNSCCs, including those OPSCCs
unrelated to HPV) typically occur in patients older
than 60 years with a history of heavy smoking and
high alcohol intake; HPV-driven OPSCCs affect
a younger population, with a median age at diag-
nosis of younger than 60 years and often with little
or no smoking history.3
Rates of HPV-negative (HPV2) HNSCC have
begun to decline in the United States, Europe, and
Australia; by contrast, HPV-driven OPSCC incidence
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is rapidly increasing in these countries.4 Although prophylactic
vaccination against hrHPV types has the potential to prevent HPV-
driven OPSCC, the sustained lifetime risk of oral hrHPV infection,
coupled with a later age at diagnosis than cervical cancer, has led to
the prediction that it will be at least 2060 before the current rising
trend is reversed, emphasizing the need to correctly diagnose and
treat these tumors.3 The clinical behavior of HPV-driven OPSCC
also differs fromHPV2 disease, having signiﬁcantly better progression-
free and overall survival.5,6 These observations have led to HPV status
becoming a routine molecular test for patients with OPSCC, and also
have resulted in clinical trials examining de-intensiﬁcation of treatment
of these patients in an attempt to reduce the morbidity associated
with the aggressive chemoradiotherapy regimens used for HNSCC.7
hrHPV DNA has been detected in tumors from other head
and neck sites (non-OPSCCs) at varying frequencies of 5% to 15%,
raising an important question as to whether these tumors are truly
HPV driven and, if so, what implications this may have for their
clinical behavior and management.8-11 Previous studies in this area
have been limited by the fact that HPV DNA detection is not a very
reliable marker of HPV causation, whereas detection of the
p16INK4A tumor suppressor protein by immunohistochemistry (a
clinical biomarker for HPV+ OPSCC) seems much less speciﬁc
outside of the oropharynx; thus the signiﬁcance of HPV detection
in non-OPSCC remains unclear.8,10
In OPSCC, detection of transcripts encoding the E6 and E7
viral oncogenes is the gold standard for HPV causation and
characteristic molecular proﬁles have been identiﬁed for these
tumors.12,13 We investigated the role of HPV in non-OPSCC by
examining molecular proﬁles of these tumors and comparing them
to proﬁles we established from meta-analyses of known HPV-
driven tumors and tumor models. Using machine learning, we
generated gene expression and DNA methylation-based classiﬁers
to predict the HPV status of 520 RNA-sequenced and 464methylation-
proﬁled HNSCCs that have now been proﬁled by The Cancer Genome
Atlas (TCGA) project, including 75HPV transcript-positive tumors (54
OPSCC, 21 non-OPSCC).14 We also evaluated the mutational spectra,
genomic alterations, and morphologic characteristics previously shown
to characterize HPV-driven HNSCC. Finally, we investigated the
prognostic signiﬁcance of HPV involvement outside of the oro-
pharynx and related this to differences in the immune microen-
vironment between HPV-driven HNSCCs from different sites.
METHODS
Gene expression microarray data were downloaded from Array Express15
(www.ebi.ac.uk/arrayexpress). TCGA HNSCC molecular data and clinical
meta-data were obtained from TCGA Data Portal (https://tcga-data.nci.
nih.gov/tcga/) and the University of California, Santa Cruz, Cancer
Browser (https://genome-cancer.ucsc.edu/), respectively. HPV transcript
detection and quantiﬁcation were conducted as described previously.16
Data processing and analysis were conducted using open-source tools in
the R programming environment. The complete code used for all analyses
is available from the authors upon request. High-resolution images from
hematoxylin and eosin (H&E) –stained slides (TCGA digital slide archive,
http://cancer.digitalslidearchive.net/) were scored blinded to anatomic site
for tumor grade and tumor-inﬁltrating lymphocyte (TIL) content by a
pathologist (G.J.T.), as described previously.17 For detailed descriptions of
all methods, see the Data Supplement.
RESULTS
Meta-Analysis Defines a Cross-Tissue Transcriptional
Signature for HPV-Driven Carcinogenesis
We conducted a meta-analysis of seven gene expression
microarray (U133A, U133+2) studies that included tissue samples
and cell-line models representing normal epithelium (n = 69),
HPV2 (n = 55), and HPV-driven (n = 138) tumors18-24 (Data
Supplement Table A1). Effect size combinationwas used to account
for cross-study/cross-platform batch effects.
A total of 159 genes were differentially expressed in the HPV-
driven samples (false discovery rate [FDR], 0.01; greater than two-
fold change; Data Supplement Table A2). Differentially expressed
gene (DEG) signature members showed a consistent pattern of
deregulation across the datasets, as visualized by clustering
(Clustering Index: range, 0% to 4.2%; Fig 1; Data Supplement
Methods). Signature gene expression was also stronger in late
passage/transformed HPV+ keratinocytes than in cells proﬁled
immediately after HPV16 infection19 (Data Supplement Fig A1A).
Furthermore, analysis of a gene expression dataset from mesen-
chymal stem cells transducedwith E6 and/or E725 demonstrated that
the signature genes were modulated by HPVoncogenes not only in
a cross-tissue fashion but also in different cellular lineages (Data
Supplement Fig A1B).
The 159 DEG Signature Serves as a Functional Readout
for HPV Oncogene Activity
Consistent with published gene expression signatures for HPV-
associated cancers,18,20,26-29 placing our DEG signature genes in
a functional context using Ingenuity Pathway Analysis (Qiagen,
Redwood City, CA) revealed expression changes consistent with
remodeling of cell cycle progression by E7; notably CDKN2A and
CCNE overexpression and CCND1 downregulation (Data Sup-
plement Fig A2). Upstream regulatory analysis indicated in-
hibition of p53 and activation of E2F, again consistent with the
well-characterized actions of the HPV oncoproteins on these
pathways30 (Data Supplement Table A3). The 159-DEG signature
also contains multiple genes previously found to be dysregulated
in HPV-associated cancers, such as the meiotic synaptonemal
complex component SYCP2, members of the replication licensing
complex and kallikrein genes.13 Taken together, the expression
signature reﬂects a causal role for HPV in these tumors.
HPV Transcript-Positive OPSCC and Non-OPSCC Share
Common Gene Expression Patterns
Next, we analyzed TCGA HNSC dataset,31 for which RNA-
sequencing data are now available from 520 samples.14 We detected
HPV transcripts in 54 of 80 OPSCC samples (67.5%) and 21 of 440
non-OPSCCs (4.8%); these are termed HPV+ (Data Supplement
Table A4). Of the 159 expression signature genes, 127 were dif-
ferentially expressed between HPV+ and HPV2 samples (FDR ,
0.01) in this data set. Almost all HPV+ samples (69 of 75) clustered
together regardless of anatomic subsite, with OPSCCs and non-
OPSCCs interspersed (Fig 2A).
To test whether this gene set can accurately predict HPV
status, we used two machine-learning approaches (the k-Nearest
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Neighbors [k-NN] algorithm and Random Forests [RF]; Salford
Systems, San Diego, CA) to build classiﬁers. Both models per-
formed well, returning out-of-fold kappa values (a measure of
classiﬁer accuracy) of 0.96 by RF and 0.94 by k-NN. The RF model
correctly predicted all 445 HPV2 andmisclassiﬁed four of 75HPV+
tumors (three non-OPSCC, one OPSCC), whereas the k-NNmodel
misclassiﬁed four HPV+ and three HPV2 tumors. Thus, the HPV
status of OPSCCs and non-OPSCCs can be predicted using clas-
siﬁers based upon our 159-DEG signature.
HPV Transcript-Positive OPSCC and Non-OPSCC
Display Similar Genome-Wide DNA Methylation
Landscapes
In addition to characteristic gene expression changes, several
studies have reported distinct DNA methylation proﬁles between
HPV+ and HPV2 OPSCC, with HPV+ OPSCCs more closely
resembling HPV+ cervical cancers than either HPV2 OPSCC or
lung squamous carcinoma.31-33 Using genome-wide DNA meth-
ylation proﬁles for only TCGA OPSCC samples (50 HPV+, 20
HPV2), we deﬁned a 468-methylation variable position (MVP)
signature (change in b [delta beta; dB] $ 0.4; FDR , 0.001; Data
Supplement Table A5). When applied to the entire data set, this
MVP signature clustered 60 of 69 HPV+ HNSCCs together,
regardless of anatomic subsite (Fig 2B) and classiﬁers built using
k-NN (k = 0.93; none of 395 HPV2 and seven of 69 HPV+
tumors misclassiﬁed) or RF (k = 0.92; two of 395 HPV2
samples, seven of 69 HPV+ samples misclassiﬁed) were able
to predict the HPV status of non-OPSCCs as well as OPSCCs.
These results support the conclusions, on the basis of gene
expression data, that HPV+ OPSCCs and non-OPSCCs are
molecularly similar and distinguishable from HPV2 HNSCCs.
These similarities in transcriptome and methylome proﬁles are
further evident when visualized on multidimensional scaling
plots (Data Supplement Fig A3). No MVPs differed between
HPV+ OPSCC and HPV+ non-OPSCC at an FDR of 0.01/dB
. 0.4, and only 19 differed at dB . 0.3.
HPV Oncogene Transcript Levels Do Not Vary Between
HPV+ OPSCC and Non-OPSCC
Expression of the E6 and E7 viral oncogenes increases during
HPV-driven tumor development and cells from these tumors are
dependent on their continued expression. Assuming that if the
HPV+ non-OPSCCs are, indeed, HPV-driven, they should express
comparable E6/E7 levels as the HPV+ OPSCCs. We compared the
levels of these transcripts and observed no difference between
the two groups (Fig 2C). HPV+ non-OPSCCs, therefore, clearly
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Fig 1. Human papillomavirus (HPV)-driven
tumors display a common gene expression
signature.Meta-analysis identiﬁed179 probes
mapping to 159 gene probes as being sig-
niﬁcantly differentially expressed between
HPV+ tumors and HPV2 controls (tumor or
normal). Annotations represent sample type
data where relevant, and HPV status. CESC,
cervical squamous cell carcinoma; HNSCC,
squamous cell carcinoma of the head and
neck; VIN, vulval intraepithelial neoplasia.
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express levels of E6 and E7 sufﬁcient for the growth and survival of
known HPV-driven tumors.
Genomic Similarities Between HPV+ OPSCC and Non-
OPSCC
Having observed strong similarities between HPV+ OPSCC
and non-OPSCC at the gene expression and epigenetic levels, we
next examined the genomic features of these tumors. We pre-
viously reported elevated fractions of mutations attributable to
deoxycytidine deaminase (APOBEC) activity in HPV+ HNSCC.34
Furthermore, APOBEC3B, previously implicated in this muta-
tional process,35 was part of our gene expression signature (Data
Supplement Table A2). The larger set of 502 HNSCCs that have
now been exome sequenced by TCGA (including 68 HPV+)
allowed us to compare enrichment for APOBEC signature mu-
tations (C.T or C.G mutations occurring within the TCW tri-
nucleotide motif, where W = A or T) in OPSCC versus non-
OPSCC (Data Supplement Fig A4). Controlling for smoking
history (which deﬁnes a separate subgroup within HPV+ OPSCC
with respect to survival and APOBEC signature mutations5,36,37),
HPV status remains a strong predictor for APOBEC independent
of anatomic site (odds ratio, 3.07; P , 2.2 3 10216), with
HPV+ non-OPSCCs displaying an even higher proportion of
APOBEC signature mutations than HPV+ OPSCC (odds ratio,
1.29; P = 2.2 3 1029), again consistent with an HPV-driven
etiology.
In addition to differences in global mutational signatures,
HPV2 and HPV+ OPSCCs display characteristic mutations and/
or copy number alterations. TP53, CDKN2A, and CCND1 al-
terations are almost exclusive to HPV2 OPSCCs, in which they
occur at high frequency.31,38-41 In HPV+ OPSCCs, E6-mediated
p53 degradation removes selection pressure for TP53 mutations,
and bypass of the G1/S checkpoint by E7 likewise obviates
pressure to acquire CDKN2A or CCND1 alterations.40,42 As
expected, we observed high frequencies of TP53 mutations,
CDKN2A mutations, deletions, and CCND1 ampliﬁcations in
HPV2 HNSCCs, and very low frequencies of these alterations in
HPV+ OPSCC. Again, HPV+ non-OPSCC tumors closely re-
sembled HPV+ OPSCCs (Table 1). Taken together, our molec-
ular analyses strongly implicated HPV as a driver in 72 of 75
transcript-positive HNSCCs, and subsequent analyses focused on
these tumors, hereafter termed HPV-driven (Data Supplement
Methods).
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Fig 2. Molecular similarities between HPV
transcript-positive tumors from different ana-
tomic subsites. Heat maps show clustering of
The Cancer Genome Atlas head and neck
squamous cell carcinoma tumors using either
(A) gene expression data (RNA-seq, n = 520;
Illumina, San Diego, CA), on the basis of our
159-gene HPV signature or (B) DNA methyla-
tion data (Illumina 450k array, n = 464), on the
basis of our 468 methylation variable position
signature. Annotation bars indicate HPV status
by RNA-seq analysis, OPSCC/non-OPSCC lo-
cation, and predicted HPV status using our
Random Forests classiﬁer. HPV+ tumors gen-
erally clustered together, with non-OPSCC
HPV+ tumors distributed among HPV+
OPSCCs. The gene expression heat map
represents z-scores and the DNA methylation
heat map displays b values. (C) Comparison of
reads from thebicistronicHPVE6/E7 transcripts
in OPSCC and non-OPSCC cases. HPV, human
papillomavirus; nonOro, nonoropharyngeal
head and neck cancer; OPSCC, oropharyngeal
squamous cell carcinoma;Oro, oropharyngeal.
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HPV-Driven Non-OPSCCs Frequently Display the
Basaloid Morphology Typical of HPV-Driven OPSCCs
To complement our molecular observations, we conducted
histopathological analysis, grading those TCGA cases for which
evaluable images of H&E-stained sections were available through
TCGA Digital Image Archive. As expected, the majority (39 of 41)
HPV+ OPSCC cases displayed a characteristic basaloid (poorly
differentiated) morphology, which has previously been linked to
their origin in nonkeratinizing tonsillar crypt epithelium.43
Strikingly, whereas HNSCCs arising at other sites are typically
keratinizing (well to moderately differentiated), 11 of the evaluable
15 HPV+ non-OPSCCs also displayed the basaloid morphol-
ogy characteristic of the OPSCCs (Data Supplement Table A6).
Consistent with these observations, comparison of global cyto-
keratin gene expression proﬁles revealed an intermediate pattern in
the HPV-driven non-OPSCCs, suggesting they are determined by
a combination of both HPV and anatomic site (Data Supplement
Fig A5).
HPV-Driven Tumors Show Different Prognosis by
Anatomic Subsite
Patients with OPSCC with an HPVetiology show signiﬁcantly
improved survival compared with those with HPV2 disease.5,6
Having demonstrated that HPV plays a causative role in transcript-
positive non-OPSCC, we examined whether patients with these
tumors display a similarly favorable prognosis. Kaplan-Meier
analysis of TCGA cohort stratiﬁed into four groups by tumor
HPV status and anatomic subsite suggested improved overall sur-
vival (OS) speciﬁcally in HPV-driven OPSCC (Fig 3). Accordingly,
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Table 1. Hallmark Genomic Alterations by Anatomic Site and HPV Status*
Group TP53 Mutation CDKN2A Mutation CCND1 Ampliﬁcation CDKN2A Deletion
HPV+ OPSCC 0 of 50 (0) 0 of 50 (0) 6 of 54 (11.1) 4 of 54 (7.4)
HPV+ non-OPSCC 1 of 18 (5.5) 0 of 18 (0) 3 of 21 (14.2) 3 of 21 (14.2)
HPV2 OPSCC 23 of 25 (92) 5 of 25 (20) 19 of 26 (73.7) 22 of 26 (84)
HPV2 non-OPSCC 336 of 409 (82) 107 of 409 (26) 197 of 413 (47.6) 281 of 413 (68)
NOTE: Data given as proportion (%).
Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma.
*Proportions represent number of samples with genomic alteration out of total samples with data available.
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oropharyngeal location was associated with longer OS in HPV-
driven tumors in multivariable analysis controlling for variables (ie,
age, smoking, T stage, and N stage) previously associated with
prognosis in HPV-driven disease.5,17
Anatomic Subsite Is Associated With Differences in
Lymphocyte Infiltration and Activation
In addition to age, stage, and smoking history, TIL levels are
reported to be associated with survival in HPV-driven OPSCC,
with low TIL numbers identifying a subgroup of patients with
poor prognosis and similar survival rates to those with HPV2
OPSCCs.17 The importance of the immune system in shaping the
evolution of HPV-driven OPSCC is also reﬂected by the high levels
of programmed death ligand 1 expressed by these tumors.44 There-
fore, we compared TIL levels between HPV-driven OPSCC and non-
OPSCC by measuring CD4 (helper/regulatory T lymphocyte) and
CD8A/CD8B (cytotoxic T lymphocyte) mRNA abundance; we
found signiﬁcantly higher levels of both mRNAs in OPSCC (Fig
4A). Consistent with this, we also observed increased TILs in
H&E-stained sections17 from HPV-driven OPSCCs (Cochran-
Armitage trend test, P = .046; Data Supplement Table A6) and
found increased expression of multiple T-cell effector markers in
HPV-driven OPSCC (Data Supplement Fig A6).
Given the importance of immune checkpoints45,46 in mod-
ulating antitumor immune responses and the observation that
PD1-expressing TILs are associated with favorable prognosis in
HPV-driven OPSCC,47 we next investigated the clinical impact of
TIL levels and their effector and immune checkpoint activity.
Clustering HPV-driven tumors on the basis of their expression of
a panel of T-cell genes denoting lineage, activation, and immune
checkpoint expression revealed two clusters (Fig 4B). The low
expression (immune-depleted) cluster was strongly enriched for
non-OPSCCs (14 of 18 non-OPSCCs and 18 of 54 OPSCCs), with
immune enrichment associated with longer OS in multivariable
analysis (Fig 4C; Table 2). Finally, we examined relationships
between the HPV-driven tumors and a previously published gene
co-expression module (M1) enriched for genes associated with
CD8+ T cells and improved survival in HNSCC (Fig 4D).48
Gene expression in TIL-high HPV-driven tumors was cor-
related with this module (r = 0.46; 95% CI, 0.44 to 0.49; P , 2.2 3
10216). HPV-driven non-OPSCCs, however, were inversely correlated
with M1 (r =20.65; 95% CI,20.67 to20.63; P, 2.23 10216) and
were, instead, mostly correlated (r = 0.66; 95% CI, 0.64 to 0.67;
P , 2.2 3 10216) with a module (M2) associated with upregulated
glucose metabolism and poor outcome, overrepresented in tumors of
the basal subtype not previously linked to HPV-driven HNSCC.48-50
Overall, the HPV-driven OPSCCs and non-OPSCCs were very
similar; we found only 67 DEGs (Data Supplement Table A7) and
no signiﬁcant MVPs. However, taken together, our analyses reveal
a clear, survival-associated difference in lymphocyte inﬁltration
between HPV-driven OPSCC and non-OPSCC.
DISCUSSION
The importance of HPV in OPSCC and its implications for patient
treatment and the design of clinical trials are well established. HPV
is detected at lower frequencies in non-OPSCC, where its biologic
role and clinical relevance are unclear.We hypothesized that if HPV
were playing a driver role in these tumors, they would share
molecular proﬁles of knownHPV-driven cancers. Our study shows
HPV+ non-OPSCCs do, indeed, share a gene expression signature
consistent with an HPV-driven etiology. Furthermore, HPV+
HNSCCs are similar (and distinct from HPV2 HNSCCs) at the
epigenetic and genomic levels. HPV+ non-OPSCCs also frequently
display the basaloid morphology that characterizes HPV+ OPSCC.
This ﬁnding, also supported by observations from HPV-associated
anogenital and sinonasal cancers, is consistent with a role for HPV
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Fig 3. Differences in overall survival by HPV
status and anatomic subsite. Kaplan-Meier curves
display overall survival in The Cancer Genome Atlas
cohort for OPSCC (n = 77) and non-OPSCC (n = 432)
by HPV status. The table indicates the number of
patients still at risk by year. Statistics are from
multivariable Cox regression controlling for age,
smoking history (more or fewer than 10 pack-years),
T stage (T1/2 v T3/4) and N stage (N0-N2a v N2b-
N3). HPV, human papillomavirus; HR, hazard ratio;
OPSCC, oropharyngeal squamous cell carcinoma.
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in blocking the differentiation of cells that would normally give rise
to keratinizing epithelia.51,52
Our ﬁndings suggest that viral etiology alone is insufﬁcient to
confer favorable prognosis in HNSCC and that this effect is largely
limited to the oropharnynx; among non-OPSCC cases, any sur-
vival beneﬁt of HPV seems minimal (hazard ratio, 0.82; 95% CI,
0.38 to 1.76; P = .63). These ﬁndings are supported by two
previous studies, in which p16 expression in non-OPSCC was
associated with either a more limited or no improvement in
OS.8,10 We acknowledge that given the possible heterogeneity
between tumors from different anatomic head and neck sub-
sites, it is not ideal to class “non-OPSCC” as a single group—a
fact also accepted by Chung and colleagues8 as a limitation in
their prognostic analysis of p16 expression in non-OPSCC. We
also recognize that although we see a clear difference in OS
and lymphocyte inﬁltration and activity between HPV-driven
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Fig 4. Enhanced lymphocyte inﬁltration
in HPV-driven OPSCC. (A) Variance stabi-
lization transformed mRNA levels of TIL
markers CD4, CD8A, and CD8B. Each was
signiﬁcant at a false discover rate , 0.05
(Wilcoxon’s rank-sum test) comparing HPV-
driven OPSCCwith HPV-driven non-OPSCC.
(B) The expression heat map of immune
checkpoint gene transcripts highlights a low
expression and a moderate/high expression
cluster within HPV-driven squamous carci-
noma of the head and neck (HNSCC); an-
notation bars represent anatomic subsite
and cluster allocation from consensus clus-
tering. (C) Kaplan-Meier curve of HPV+
HNSCC stratiﬁed by TIL status. The table
represents the number at risk at the given
time points. Statistics are from multivariable
Cox regression controlling for age, smoking
history (more or fewer than 10 pack-years),
subsite, T stage (T1/2 v T3/4) and N stage
(N0-N2a v N2b-N3). This also is compared in
Table 2. (D) Weighted correlation network
analysis network graphs. Each gene is la-
beled by color according to correlation with
the indicated tumor subtype. Red and blue
show positive and negative correlation, re-
spectively. HPV, human papillomavirus; Neg,
negative; OPSCC: oropharyngeal squamous
cell carcinoma; Oro, oropharyngeal; Pos,
positive; TIL, tumor-inﬁltrating lymphocyte.
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OPSCC and non-OPSCC, there were insufﬁcient data on treat-
ment in this cohort to permit its inclusion as a variable in
multivariable analysis. Investigation of a larger, uniformly treated
patient cohort is needed, therefore, to conﬁrm that the difference
in prognosis is independent of possible differences in patient
management between OPSCC and non-OPSCC. Notably, in
OPSCC, the improved prognosis of patients with HPV-driven
disease has been shown in several studies to be independent of
treatment modality,53-55 arguing for a tumor-intrinsic factor in
driving this survival difference. It has been suggested that this is
due, at least in part, to increased radiosensitivity, perhaps resulting
from retention of wild-type TP53.56 The almost universal retention of
wild-type TP53 in HPV-driven HNSCC (Table 1) suggests an al-
ternative explanation for the survival difference by subsite.
The difference in TIL levels between HPV-driven OPSCC and
non-OPSCC suggests a fundamentally different immune response
to these tumors. Interestingly, in their analysis of the initial HNSCC
dataset of 279 tumors, 14 of which were HPV transcript-positive
non-OPSCCs, TCGA classiﬁed several as belonging to the basal
transcriptional subtype initially identiﬁed by Chung and colleagues.31,49
Our analysis demonstrates that these tumors are, in fact, highly similar
to HPV-driven OPSCCs of the atypical subtype, and that they are also
HPV-driven but lack the lymphocyte inﬁltration associated with im-
proved outcomes in OPSCC. This observation potentially explains
the survival differences between HPV-driven tumors at these sites
and implies that there is something unique to the oropharynx that
enhances the immune response to HPV-driven tumors (but not
HPV2 tumors) arising at this location.
Our analysis identiﬁes and provides important insight into a new
patient population, with implications for both cancer prevention and
treatment. Using multiomic TCGA data has uniquely allowed us to
build a comprehensive molecular map of HPV+ HNSCCs and to use
HPV transcript detection as ourmarker for HPV positivity throughout,
thus identifying a signiﬁcant role for HPVoutside the oropharynx and
avoiding the previously documented pitfalls of either HPVDNAor p16
detection.8,57 HPV transcript-positive non-OPSCCs are HPV driven
andwould likely beneﬁt fromHPV-targeted therapies (and be prevented
by prophylactic HPV vaccination). The relatively poor prognosis
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of HPV-driven non-OPSCC, however, argues against treatment de-
escalation for these tumors, whereas clear differences in the immune
microenvironment suggest wemay expect altered responses to immune
checkpoint blockade. Fromaprecisionmedicineperspective,HPV-driven
non-OPSCC cases should be identiﬁed and considered as a distinct entity
with respect to both HPV2 HNSCC and HPV-driven OPSCC.
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